Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
18.92
+0.46 (2.49%)
At close: Nov 20, 2024, 4:00 PM
18.54
-0.38 (-2.01%)
Pre-market: Nov 21, 2024, 6:07 AM EST
Capricor Therapeutics Employees
As of December 31, 2023, Capricor Therapeutics had 102 total employees, including 101 full-time and 1 part-time employees. The number of employees increased by 28 or 37.84% compared to the previous year.
Employees
102
Change (1Y)
28
Growth (1Y)
37.84%
Revenue / Employee
$227,726
Profits / Employee
-$334,438
Market Cap
860.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Healthcare Services Group | 33,400 |
Embecta | 2,200 |
Paragon 28 | 574 |
Relay Therapeutics | 323 |
Liquidia | 145 |
Nuvation Bio | 51 |
Tyra Biosciences | 49 |
ArriVent BioPharma | 40 |
CAPR News
- 7 days ago - Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - GlobeNewsWire
- 6 weeks ago - Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 6 weeks ago - Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - GlobeNewsWire